Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.

To evaluate the response of extramedullary disease following CAR T-cell therapy.

To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

• To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
• To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

• To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
• To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
• To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
• To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
• To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
• To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
• To evaluate the response of extramedullary disease following CAR T-cell therapy.
• To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
• To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
• To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
• To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
• To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
• To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
• To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

• Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.

Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.

All IPD recorded in the medical record will be shared with intramural investigators upon request.

Clinical data available during the study and indefinitely.

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.